Seaport Therapeutics Raises $225 Million in Series B Financing

Seaport Therapeutics Raises $225 Million in Series B Financing

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On October 21, 2024, Seaport Therapeutics, a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, announced the closing of its $225 million Series B financing round. The financing was led by General Atlantic, a leading global growth investor, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures and co-founder PureTech Health also participated. This latest round will help Seaport advance its clinical-stage pipeline of first and best-in-class medicines through important clinical milestones, along with further advancing its Glyph™ technology platform, which has demonstrated clinical proof-of-concept.

The WilmerHale team representing Seaport consisted of Stuart Falber, Riley O’Brien and Emily Ivers.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel